Gu Xiangming, Palmer Andre F
William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, Ohio, USA.
Biotechnol Prog. 2024 Nov-Dec;40(6):e3501. doi: 10.1002/btpr.3501. Epub 2024 Jul 30.
The biodistribution of many therapeutics is controlled by the immune system. In addition, some molecules are cytotoxic when not encapsulated inside of larger cellular structures, such as hemoglobin (Hb) encapsulation inside of red blood cells (RBCs). To counter immune system recognition and cytotoxicity, drug delivery systems based on red blood cell membrane fragments (RBCMFs) have been proposed as a strategy for creating immunoprivileged therapeutics. However, the use of RBCMFs for drug delivery applications requires purification of RBCMFs at large scale from lysed RBCs free of their intracellular components. In this study, we were able to successfully use tangential flow filtration (TFF) to remove >99% of cell-free Hb from lysed RBCs at high concentrations (30%-40% v/v), producing RBCMFs that were 2.68 ± 0.17 μm in diameter. We were also able to characterize the RBCMFs more thoroughly than prior work, including measurement of particle zeta potential, along with individual TFF diacycle data on the cell-free Hb concentration in solution and time per diacycle, as well as concentration and size of the RBCMFs. In addition to purifying RBCMFs from lysed RBCs, we utilized a hypertonic solution to reseal purified RBCMFs encapsulating a model protein (Hb) to yield resealed Hb-encapsulated RBC ghosts (Hb-RBCGs). TFF was then compared against centrifugation as an alternative method for removing unencapsulated Hb from Hb-RBCGs, and the effects that each washing method on the resulting Hb-RBCG biophysical properties was assessed.
许多治疗药物的生物分布受免疫系统控制。此外,一些分子在未封装于较大细胞结构内时具有细胞毒性,例如血红蛋白(Hb)封装于红细胞(RBC)内。为对抗免疫系统识别和细胞毒性,基于红细胞膜片段(RBCMFs)的药物递送系统已被提出,作为创建免疫豁免治疗药物的一种策略。然而,将RBCMFs用于药物递送应用需要从裂解的红细胞中大规模纯化RBCMFs,且不含其细胞内成分。在本研究中,我们能够成功地使用切向流过滤(TFF)从高浓度(30%-40% v/v)的裂解红细胞中去除>99%的无细胞Hb,产生直径为2.68±0.17μm的RBCMFs。我们还能够比之前的工作更全面地表征RBCMFs,包括测量颗粒zeta电位,以及关于溶液中无细胞Hb浓度和每个循环时间的单个TFF循环数据,以及RBCMFs的浓度和大小。除了从裂解红细胞中纯化RBCMFs外,我们还利用高渗溶液重新密封封装了模型蛋白(Hb)的纯化RBCMFs,以产生重新密封的Hb封装红细胞幽灵(Hb-RBCGs)。然后将TFF与离心法进行比较,作为从Hb-RBCGs中去除未封装Hb的替代方法,并评估每种洗涤方法对所得Hb-RBCG生物物理特性的影响。